AP2004003084A0 - 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors - Google Patents
3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitorsInfo
- Publication number
- AP2004003084A0 AP2004003084A0 APAP/P/2004/003084A AP2004003084A AP2004003084A0 AP 2004003084 A0 AP2004003084 A0 AP 2004003084A0 AP 2004003084 A AP2004003084 A AP 2004003084A AP 2004003084 A0 AP2004003084 A0 AP 2004003084A0
- Authority
- AP
- ARIPO
- Prior art keywords
- imidazolyl
- tafia inhibitors
- alkoxypropanoic
- acids
- alky
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- -1 Aromatic heterocycle Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0201389A GB0201389D0 (en) | 2002-01-22 | 2002-01-22 | 3-(imidazolyl)-2-alkoxypropanoic acids |
| GB0202027A GB0202027D0 (en) | 2002-01-29 | 2002-01-29 | 3-(imidazolyl)-2-alkoxypropanoic acids |
| PCT/IB2003/000060 WO2003061652A1 (en) | 2002-01-22 | 2003-01-10 | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2004003084A0 true AP2004003084A0 (en) | 2004-09-30 |
Family
ID=27614792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2004/003084A AP2004003084A0 (en) | 2002-01-22 | 2003-01-10 | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1467731A1 (pl) |
| JP (1) | JP2005520811A (pl) |
| KR (1) | KR20040077775A (pl) |
| CN (1) | CN1620291A (pl) |
| AP (1) | AP2004003084A0 (pl) |
| AR (1) | AR038197A1 (pl) |
| BR (1) | BR0307016A (pl) |
| CA (1) | CA2472238A1 (pl) |
| EA (1) | EA200400716A1 (pl) |
| EC (1) | ECSP045200A (pl) |
| HR (1) | HRP20040659A2 (pl) |
| IL (1) | IL162677A0 (pl) |
| IS (1) | IS7310A (pl) |
| MA (1) | MA27167A1 (pl) |
| MX (1) | MXPA04006573A (pl) |
| NO (1) | NO20043457L (pl) |
| OA (1) | OA12756A (pl) |
| PA (1) | PA8563501A1 (pl) |
| PE (1) | PE20030929A1 (pl) |
| PL (1) | PL371487A1 (pl) |
| TN (1) | TNSN04121A1 (pl) |
| TW (1) | TW200302094A (pl) |
| UY (1) | UY27615A1 (pl) |
| WO (1) | WO2003061652A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051384A1 (en) * | 2003-11-25 | 2005-06-09 | Pfizer Limited | Stabilised pharmaceutical compositions |
| JP2008536923A (ja) * | 2005-04-18 | 2008-09-11 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心筋の再灌流の増強およびｐｃｉの容易化のためのｔａｆｉ阻害剤の使用 |
| WO2010050525A1 (ja) | 2008-10-29 | 2010-05-06 | 大正製薬株式会社 | ＴＡＦＩａ阻害活性を有する化合物 |
| US8987242B2 (en) | 2008-12-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXA inhibitors |
| JP2012511008A (ja) * | 2008-12-05 | 2012-05-17 | 持田製薬株式会社 | ＩＸａ因子阻害薬としてのモルホリノン化合物 |
| BR112012023412A2 (pt) | 2010-03-18 | 2018-05-08 | Daiichi Sankyo Company, Limited | composto, drogra farmacêutica, inibidor de tafia, promotor de fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, e, uso de um composto. |
| EP2548871B1 (en) * | 2010-03-18 | 2017-07-19 | Daiichi Sankyo Company, Limited | Cycloalkyl-substituted imidazole derivative |
| KR20160018557A (ko) | 2013-06-10 | 2016-02-17 | 사노피 | TAFIa의 저해제로서의 마크로사이클릭 우레아 유도체, 이의 제법 및 의약품으로서의 이의 용도 |
| US20190117624A1 (en) | 2016-03-29 | 2019-04-25 | Daiichi Sankyo Company, Limited | Therapeutic agent for inflammatory bowel diseases |
| MY202326A (en) | 2017-09-14 | 2024-04-24 | Daiichi Sankyo Co Ltd | Compound having cyclic structure |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| ATE447557T1 (de) * | 2000-08-17 | 2009-11-15 | Pfizer Ltd | Substitutuierte imidazole als tafia inhibitoren |
-
2003
- 2003-01-10 EA EA200400716A patent/EA200400716A1/ru unknown
- 2003-01-10 BR BR0307016-6A patent/BR0307016A/pt not_active IP Right Cessation
- 2003-01-10 KR KR10-2004-7011370A patent/KR20040077775A/ko not_active Ceased
- 2003-01-10 HR HR20040659A patent/HRP20040659A2/hr not_active Application Discontinuation
- 2003-01-10 IL IL16267703A patent/IL162677A0/xx unknown
- 2003-01-10 JP JP2003561596A patent/JP2005520811A/ja active Pending
- 2003-01-10 WO PCT/IB2003/000060 patent/WO2003061652A1/en not_active Ceased
- 2003-01-10 PL PL03371487A patent/PL371487A1/pl unknown
- 2003-01-10 AP APAP/P/2004/003084A patent/AP2004003084A0/en unknown
- 2003-01-10 EP EP03700059A patent/EP1467731A1/en not_active Withdrawn
- 2003-01-10 CN CNA03802599XA patent/CN1620291A/zh active Pending
- 2003-01-10 OA OA1200400190A patent/OA12756A/en unknown
- 2003-01-10 MX MXPA04006573A patent/MXPA04006573A/es unknown
- 2003-01-10 CA CA002472238A patent/CA2472238A1/en not_active Abandoned
- 2003-01-16 TW TW092100889A patent/TW200302094A/zh unknown
- 2003-01-17 PE PE2003000058A patent/PE20030929A1/es not_active Application Discontinuation
- 2003-01-20 UY UY27615A patent/UY27615A1/es not_active Application Discontinuation
- 2003-01-21 AR ARP030100165A patent/AR038197A1/es unknown
- 2003-01-22 PA PA20038563501A patent/PA8563501A1/es unknown
-
2004
- 2004-06-14 IS IS7310A patent/IS7310A/is unknown
- 2004-06-30 TN TNP2004000121A patent/TNSN04121A1/en unknown
- 2004-07-15 MA MA27786A patent/MA27167A1/fr unknown
- 2004-07-22 EC EC2004005200A patent/ECSP045200A/es unknown
- 2004-08-19 NO NO20043457A patent/NO20043457L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR038197A1 (es) | 2005-01-05 |
| CN1620291A (zh) | 2005-05-25 |
| UY27615A1 (es) | 2003-08-29 |
| IL162677A0 (en) | 2005-11-20 |
| ECSP045200A (es) | 2004-08-27 |
| PE20030929A1 (es) | 2003-11-05 |
| OA12756A (en) | 2006-07-03 |
| BR0307016A (pt) | 2004-11-03 |
| TNSN04121A1 (en) | 2006-06-01 |
| CA2472238A1 (en) | 2003-07-31 |
| PA8563501A1 (es) | 2004-08-31 |
| EP1467731A1 (en) | 2004-10-20 |
| PL371487A1 (pl) | 2005-06-13 |
| IS7310A (is) | 2004-06-14 |
| JP2005520811A (ja) | 2005-07-14 |
| WO2003061652A1 (en) | 2003-07-31 |
| NO20043457L (no) | 2004-08-19 |
| MA27167A1 (fr) | 2005-01-03 |
| TW200302094A (en) | 2003-08-01 |
| KR20040077775A (ko) | 2004-09-06 |
| EA200400716A1 (ru) | 2004-12-30 |
| MXPA04006573A (es) | 2004-10-04 |
| HRP20040659A2 (en) | 2004-10-31 |
| WO2003061652A8 (en) | 2004-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2282B1 (en) | Oxazole derivatives | |
| NO20021358L (no) | Alkylendiamin-substituerte heterocykler | |
| EA200601830A1 (ru) | Ортозамещённые арильные или гетероарильные амидные соединения | |
| NO20064418L (no) | Nye amido-substituerte hydroksy-6-fenylfenantridiner | |
| DE60328010D1 (de) | Heterocyclische verbindungen | |
| NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
| NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
| EA200401381A1 (ru) | 3-гетероарилзамещённые изоксазолины | |
| EA200600509A1 (ru) | Соединения пиримидотиофена | |
| CY1107903T1 (el) | Παραγωγα ακυλαμινοθειαζολης και η χρηση τους ως αναστολεις του βητα-αμυλοειδους | |
| IS2416B (is) | Pýrrólídíndíónútskipt píperídín-þalasón sem PDE4 tálmar | |
| ATE396993T1 (de) | Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität | |
| DK1265606T3 (da) | Celleadhæsionsinhibitorer | |
| TW200716531A (en) | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia | |
| MXPA04005940A (es) | Acidos 3-(imidazolil)-2-aminopropanoicos. | |
| AP2004003084A0 (en) | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors | |
| WO2003082861A3 (en) | Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases | |
| NO20062272L (no) | Fremgangsmater og sammensetninger for selektin inhibisjon | |
| NO20062348L (no) | Fremgangsmater og sammensetninger for selektin inhibisjon | |
| MY121785A (en) | Hydroxamic acid derivatives as inhibitors of the production of soluble cd23 | |
| DE60011300D1 (de) | Inhibitoren der tryptase | |
| DOP2003000564A (es) | Acidos 3-(imidazolil)-2-alcoxipropanoicos | |
| NO20062307L (no) | Spirofuropyridinarylderivater | |
| NO20020886L (no) | Nye integrin- <alfa>v<beta>3-inhibitorer | |
| MXPA05006530A (es) | Derivados de 1-n-fenilamino-1h-imidazola como inhibidores aromatasa. |